{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:24:06Z","timestamp":1782858246831,"version":"3.54.5"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clgc.2025.102411","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T17:44:05Z","timestamp":1754415845000},"page":"102411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of HRR Gene Subclass on Clinical Outcomes of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9925-9025","authenticated-orcid":false,"given":"George","family":"Dimitrov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elenko","family":"Popov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.clgc.2025.102411_bib0001","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s11864-024-01215-2","article-title":"Metastatic castration-resistant prostate cancer: advances in treatment and symptom management","volume":"25","author":"Kulasegaran","year":"2024","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102411_bib0002","article-title":"PARP inhibitors in metastatic castration-resistant prostate cancer: unraveling the therapeutic landscape","volume":"14","author":"Al-Akhras","year":"2024","journal-title":"Life (Basel)"},{"issue":"9","key":"10.1016\/j.clgc.2025.102411_bib0003","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.clgc.2025.102411_bib0004","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and Olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evidence"},{"issue":"10398","key":"10.1016\/j.clgc.2025.102411_bib0005","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2025.102411_bib0006","doi-asserted-by":"crossref","first-page":"TPS277","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS277","article-title":"Alliance A031902 (CASPAR): a randomized phase (ph) 3 trial of enzalutamide with rucaparib\/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Rao","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clgc.2025.102411_bib0007","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e17053","article-title":"Efficacy and safety of PARP inhibitors (PARPi) with immune checkpoint inhibitors (ICI) in metastatic castration-resistant prostate cancer (mCRPC): a systematic review and single-arm meta-analysis","volume":"42","author":"Gazzoni","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102411_bib0008","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrc3181","article-title":"BRCA1 and BRCA2: different roles in a common pathway of genome protection","volume":"12","author":"Roy","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"10.1016\/j.clgc.2025.102411_bib0009","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.3390\/ijms25094624","article-title":"Homologous recombination repair deficiency in metastatic prostate cancer: new therapeutic opportunities","volume":"25","author":"Piombino","year":"2024","journal-title":"Int J Molecul Sci"},{"issue":"4","key":"10.1016\/j.clgc.2025.102411_bib0010","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41391-023-00676-0","article-title":"Guidelines for genetic testing in prostate cancer: a scoping review","volume":"27","author":"Tuffaha","year":"2024","journal-title":"Prostate Can Prostatic Dis"},{"issue":"12","key":"10.1016\/j.clgc.2025.102411_bib0011","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","article-title":"ESMO guidance for reporting oncology real-world evidence (GROW)","volume":"34","author":"Castelo-Branco","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2025.102411_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: a precision oncology knowledge base","volume":"1","author":"Chakravarty","year":"2017","journal-title":"JCO Precision Oncology"},{"key":"10.1016\/j.clgc.2025.102411_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102359","article-title":"PARP inhibitors for metastatic castration-resistant prostate cancer: biological rationale and current evidence","volume":"104","author":"Bie\u0144kowski","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"10.1016\/j.clgc.2025.102411_bib0014","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a012716","article-title":"DNA damage sensing by the ATM and ATR kinases","volume":"5","author":"Mar\u00e9chal","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"14","key":"10.1016\/j.clgc.2025.102411_bib0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411418","article-title":"DNA damage repair pathways in prostate cancer: a narrative review of molecular mechanisms, emerging biomarkers and therapeutic targets in precision oncology","volume":"24","author":"Grypari","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.clgc.2025.102411_bib0016","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25094624","article-title":"Homologous recombination repair deficiency in metastatic prostate cancer: new therapeutic opportunities","volume":"25","author":"Piombino","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.clgc.2025.102411_bib0017","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41467-017-00393-y","article-title":"Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer","volume":"8","author":"Asim","year":"2017","journal-title":"Nature Communications"},{"issue":"8","key":"10.1016\/j.clgc.2025.102411_bib0018","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1158\/0008-5472.CAN-23-0628","article-title":"BRCAness, Homologous recombination deficiencies, and synthetic lethality","volume":"83","author":"Murai","year":"2023","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.clgc.2025.102411_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24108940","article-title":"Multi-gene next-generation sequencing panel for analysis of BRCA1\/BRCA2 and homologous recombination repair genes alterations metastatic castration-resistant prostate cancer","volume":"24","author":"Maloberti","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"18","key":"10.1016\/j.clgc.2025.102411_bib0020","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1158\/1078-0432.CCR-24-0919","article-title":"Improving collection and analysis of overall survival data","volume":"30","author":"Rodriguez","year":"2024","journal-title":"Clin Can Res"},{"key":"10.1016\/j.clgc.2025.102411_bib0021","article-title":"Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of clinical trials","volume":"120","author":"Iannantuono","year":"2023","journal-title":"Can Treatm Rev"},{"issue":"10","key":"10.1016\/j.clgc.2025.102411_bib0022","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"10.1016\/j.clgc.2025.102411_bib0023","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.urolonc.2023.03.002","article-title":"Financial toxicity of oral therapies in advanced prostate cancer","volume":"41","author":"Joyce","year":"2023","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102411_bib0024","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/bju.16130","article-title":"Poly(adenosine diphosphate-ribose) polymerase inhibitor combinations in first-line metastatic castrate-resistant prostate cancer setting: a systematic review and meta-analysis","volume":"132","author":"Sayyid","year":"2023","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.clgc.2025.102411_bib0025","doi-asserted-by":"crossref","first-page":"P626","DOI":"10.1016\/j.eururo.2024.12.007","article-title":"Heterogeneity of the treatment effect with PARP inhibitors in metastatic castration-resistant prostate cancer: a living interactive systematic review and meta-analysis","volume":"87","author":"Naqvi","year":"2025","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.clgc.2025.102411_bib0026","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1002\/cncr.33487","article-title":"Differential treatment outcomes in BRCA1\/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer","volume":"127","author":"Kwon","year":"2021","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2025.102411_bib0027","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/JU.0000000000001819","article-title":"Distinct response to platinum-based chemotherapy among patients with metastatic castration-resistant prostate cancer harboring alterations in genes involved in homologous recombination","volume":"206","author":"Fan","year":"2021","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102411_bib0028","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.euo.2023.09.001","article-title":"Poly (ADP-ribose) polymerase inhibitors have comparable efficacy with platinum chemotherapy in patients with BRCA-positive metastatic castration-resistant prostate cancer. A systematic review and meta-analysis","volume":"7","author":"Fazekas","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2025.102411_bib0029","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1007\/s12094-024-03506-4","article-title":"Comparative effectiveness of first-line systemic treatments for metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis","volume":"26","author":"Ai","year":"2024","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102411_bib0030","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bju.16462","article-title":"Impact of homologous recombination repair\/BReast CAncer (BRCA) gene alterations on survival in a real-world setting of metastatic prostate cancer","volume":"135","author":"Wenzel","year":"2025","journal-title":"BJU Int"},{"issue":"14","key":"10.1016\/j.clgc.2025.102411_bib0031","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1200\/JCO.23.02105","article-title":"Efficacy of poly(ADP-ribose) polymerase inhibitors by individual genes in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer: a US Food and Drug Administration pooled analysis","volume":"42","author":"Fallah","year":"2024","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.clgc.2025.102411_bib0032","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1158\/1078-0432.CCR-24-1402","article-title":"Abiraterone, Olaparib, or Abiraterone + Olaparib in first-line metastatic castration-resistant prostate cancer with DNA repair defects (BRCAAway)","volume":"30","author":"Hussain","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2025.102411_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102726","article-title":"First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC: applying clinical study findings to clinical practice in the United States","volume":"126","author":"McKay","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.clgc.2025.102411_bib0034","doi-asserted-by":"crossref","first-page":"e455","DOI":"10.1002\/bco2.455","article-title":"PARP inhibitor-based treatment in metastatic, castration-resistant prostate cancer (mCRPC): a systematic review and meta-analysis","volume":"6","author":"Roberto","year":"2025","journal-title":"BJUI Compass"},{"issue":"6","key":"10.1016\/j.clgc.2025.102411_bib0035","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/em.22505","article-title":"A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies","volume":"63","author":"Shao","year":"2022","journal-title":"Environ Mol Mutagen"},{"issue":"1","key":"10.1016\/j.clgc.2025.102411_bib0036","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/sj.cr.7310007","article-title":"The role of NBS1 in DNA double strand break repair, telomere stability, and cell cycle checkpoint control","volume":"16","author":"Zhang","year":"2006","journal-title":"Cell Res"},{"key":"10.1016\/j.clgc.2025.102411_bib0037","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.pbiomolbio.2020.11.005","article-title":"Roles of ATM and ATR in DNA double strand breaks and replication stress","volume":"161","author":"Williams","year":"2021","journal-title":"Prog Biophys Mol Biol"},{"key":"10.1016\/j.clgc.2025.102411_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113503","article-title":"Objective response rate and progression-free survival as surrogates for overall survival treatment effect: a meta-analysis across diverse tumour groups and contemporary therapies","volume":"198","author":"Shahnam","year":"2024","journal-title":"Eur J Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:43:08Z","timestamp":1772890988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325001119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1558767325001119"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102411","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of HRR Gene Subclass on Clinical Outcomes of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102411","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102411"}}